FOLH1 and prostate carcinoma: 225Ac-PSMA-617 is an alpha-emitting radioisotope-labeled derivative of PSMA-617, which targets the overexpressed PSMA seen in prostate cancer, and this therapy has demonstrated excellent therapeutic response in prostate cancer [82, 83].